TScan Therapeutics, Inc. — Form 8-K
Filed October 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-10-16 reports Item 5.02 event (officer/director departure, election, or appointment with compensatory arrangements) effective 2026-10-13. No specific names, dollar amounts, share counts, or detailed terms are visible in the filing header or document list provided; the actual narrative content describing the transaction is not included in this excerpt.
Why this rating
Routine officer transition disclosure; no material financial impact or quantum disclosed. Ordinary governance event for $56.9M-cap biotech.
Extracted items
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.